UNLIMITED TURBO LONG - NOVO-NORDISK B | Real-time Euronext Paris 06:38:38 24/05/2024 pm IST | ||
| 3.705 EUR | -5.48% |
|
| Current month | +18.97% | ||
| 1 month | +18.79% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24/24/24 | 3.705 | -5.48% |
| 23/24/23 | 3.92 | +6.23% |
| 22/24/22 | 3.69 | -0.40% |
| 21/24/21 | 3.705 | +9.29% |
| 17/24/17 | 3.39 | -5.04% |
Real-time Euronext Paris
Last update May 24, 2024 at 06:38 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| PS4NB | |
| ISIN | NLBNPNL2O250 |
| Date issued | 26/02/2024 |
| Strike | 672.1 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.54 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.92 € |
|---|---|
| Lowest since issue | 2.27 € |
| Spread | 0.01 € |
| Spread % | 0.27% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
937.4
DKK
Average target price
909.2
DKK
Spread / Average Target
-3.00%
- Stock Market
- Certificates
- PS4NB Certificat
